Press Releases

 
Press Releases
Date Title and Summary View
Feb 4, 2014 SALT LAKE CITY, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has entered into a definitive agreement to acquire Crescendo Bioscience, Inc., a global leader in autoimmune diagnostics, for $270 million in cash which will be reduced by $25 million for the repayment of a loan made to Crescendo and customa...
Jan 29, 2014 SALT LAKE CITY, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating me...
Jan 28, 2014 SALT LAKE CITY, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published details of its myVision™ Myriad Variant Classification Program in the journal Clinical Genetics. myVision is the most advanced variant classification program available to determine whether a patient's genetic variant (mu...
Jan 23, 2014 SALT LAKE CITY, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter 2014 following the close of market on Tuesday, February 4, 2014. The Company also will host a conference call on Tuesday, February 4, 2014 at 4:30 p.m. ET to discuss the fin...
Jan 23, 2014 SALT LAKE CITY, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from four studies in prostate cancer with Prolaris® and one study in renal cancer will be presented at the 2014 ASCO Genitourinary Cancers Symposium, which will be held Jan. 30-Feb. 1, 2014 in San Francisco, Calif. Prolaris is a p...
Jan 7, 2014 SALT LAKE CITY, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference, at 9:30 a.m. Pacific on January 13, 2014, at the Westin St. Francis Hotel in San Francisco, California. The pre...
Dec 14, 2013 SALT LAKE CITY, Dec. 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin response in patients with triple negative breast cancer. In th...
Dec 12, 2013 SALT LAKE CITY, Dec. 12, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the myRisk Hereditary Cancer test found 51 percent more patients with a higher risk of hereditary breast and ovarian cancer than did testing for the BRCA1 and BRCA2 genes alo...
Dec 9, 2013 BRACAnalysis® Testing Will be Performed in Phase 3 Clinical Trial SALT LAKE CITY, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Janssen Research & Development, LLC, will use Myriad's BRACAnalysis test in connection with its Phase 3 clinical trial of Yondelis® (trabectedin) in the treatm...
Dec 5, 2013 SALT LAKE CITY, Dec. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it will be hosting an investor event for research analysts and institutional investors on Thursday, December 12, 2013 at 8:30 p.m. EST in San Antonio, Texas. Mark Capone, president of Myriad Genetic Laboratories; Richard Wenstrup M.D., chief me...
Page: FirstPrevious
4
... NextLast
= add release to Briefcase